Premium
Enhancement of B‐cell secretion by blood glucose normalization in type 2 diabetes is associated with fasting C‐peptide levels
Author(s) -
CLAUSON P.,
ALVARSSON M.,
GRILL V.
Publication year - 1997
Publication title -
journal of internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.625
H-Index - 160
eISSN - 1365-2796
pISSN - 0954-6820
DOI - 10.1111/j.1365-2796.1997.tb00007.x
Subject(s) - medicine , proinsulin , endocrinology , type 2 diabetes , insulin , diabetes mellitus , glucagon , population , type 1 diabetes , c peptide , arginine , biology , biochemistry , environmental health , amino acid
. Clauson P, Alvarsson M, Grill V (Karolinska Hospital, Stockholm, Sweden). Enhancement of B‐cell secretion by blood glucose normalization in type 2 diabetes is associated with fasting Cpeptide levels. Objectives: To investigate (i) the variability of beneficial effects achieved by short‐term near‐normalization of blood glucose in type 2 diabetes patients, and (ii) the relationship of beneficial effects to individual characteristics of diabetes. Design: Arginine‐induced insulin and glucagon release tested at two glucose levels before and alter 3 days of intensive insulin treatment. Setting: The Department of Endocrinology and Diabetology, Karolinska Hospital, Stockholm, Sweden. bolic control sampled from an area‐based population of diabetes patients. Results: Levels of fasting blood glucose declined from 15.0 f 0.9 to 8.5 k 0.7 mmol L‐‘, Cpeptide from 0.81 f 0.06 to 0.49 & 0.05 nmol L‐’ and percent proinsulin (of total IRI) from 7.8 & 1.0 to 3.2 f 0.6%. At comparable glucose levels arginine‐induced insulin secretion was enhanced 46.3+19.5% (range ‐36 to 220%). Enhancement correlated with extent of blood glucose normalization and also with fasting Gpeptide levels and with overweight. Arginineinduced glucagon secretion was nonsignificantly depressed (17.2 f 7.4%, range ‐ 59 to 29%). Insulin sensitivity assessed by M: I ratio was increased by a median of 95 %. Conclusions: In type 2 diabetes patients reversibility type 2 diabetes patients reversibility function is variable. Variability is related to B‐cell mass in individual patients with type 2 diabetes.